• Pituitary disorders

Skytrofa Generic Name & Formulations

General Description

Lonapegsomatropin-tcgd 3mg, 3.6mg, 4.3mg, 5.2mg, 6.3mg, 7.6mg, 9.1mg, 11mg, 13.3mg; per prefilled cartridge; lyophilized pwd for SC inj after reconstitution; preservative-free.

Pharmacological Class

Growth hormone (GH).

How Supplied

Single-dose prefilled cartridges—4 (w. needles); Auto-Injector—1


Generic Availability


Skytrofa Indications


Growth failure in children due to inadequate secretion of endogenous growth hormone (GH).

Skytrofa Dosage and Administration


Not applicable.


<1yr (<11.5kg): not established. Give by SC inj into abdomen, buttock, or thigh; rotate inj sites. Individualize and titrate based on response. Weight-based: 0.24mg/kg, given once weekly. ≥1yr (11.5–13.9kg): 3mg/week; (14–16.4kg): 3.6mg/week; (16.5–19.9kg): 4.3mg/week; (20–23.9kg): 5.2mg/week; (24–28.9kg): 6.3mg/week; (29–34.9kg): 7.6mg/week; (35–41.9kg): 9.1mg/week; (42–50.9kg): 11mg/week; (51–60.4kg): 13.3mg/week; (60.5–69.9kg): 15.2mg/week (2 cartridges of 7.6mg each); (70–84.9kg): 18.2mg/week (2 cartridges of 9.1mg each); (85–100kg): 22mg/week (2 cartridges of 11mg each). Discontinue once epiphyseal fusion has occurred. Switching from daily somatropin therapy: wait at least 8hrs between the last dose of somatropin and the first dose of Skytrofa. Non-weight based: see full labeling.

Skytrofa Contraindications


Acute critical illness after open heart or abdominal surgery, or multiple accidental trauma or those with acute respiratory failure. Closed epiphyses. Active malignancy. Active proliferative or severe non-proliferative diabetic retinopathy. History of upper airway obstruction or sleep apnea, severe obesity, or severe respiratory impairment in children with Prader-Willi syndrome (PWS).

Skytrofa Boxed Warnings

Not Applicable

Skytrofa Warnings/Precautions


Increased mortality in those with acute critical illness (see Contraindications). Not for treatment of children with growth failure due to PWS. Increased risk of malignancies; if preexisting, complete treatment prior to Skytrofa initiation; discontinue if there is evidence of recurrent activity. History of GHD secondary to intracranial neoplasm: monitor routinely for tumor progression or recurrence. Monitor for increased growth or malignant changes of preexisting nevi. Diabetes. Obesity. Intracranial hypertension: perform routine funduscopic exam at baseline and periodically thereafter; discontinue if papilledema develops. Hypoadrenalism: monitor for reduced serum cortisol levels. Hypothyroidism. Scoliosis (monitor). Monitor thyroid function, glucose tolerance. May increase serum phosphorous, alkaline phosphatase, parathyroid hormone after therapy. Pregnancy. Nursing mothers.

Skytrofa Pharmacokinetics

See Literature

Skytrofa Interactions


May require increase in maintenance or stress doses of glucocorticoids in hypoadrenalism. May be antagonized by replacement glucocorticoids; adjust glucocorticoid dose. Concomitant drugs metabolized by CYP450 enzymes; monitor. Antidiabetic medications may need to be adjusted. Women on oral estrogen: may need higher Skytrofa dose.

Skytrofa Adverse Reactions

Adverse Reactions

Viral infection, pyrexia, cough, nausea, vomiting, hemorrhage, diarrhea, abdominal pain, arthralgia, arthritis; severe hypersensitivity reactions, fluid retention, hyperglycemia, impaired glucose tolerance, intracranial hypertension, hypoadrenalism, slipped capital femoral epiphysis (monitor), pancreatitis, lipoatrophy.

Skytrofa Clinical Trials

See Literature

Skytrofa Note

Not Applicable

Skytrofa Patient Counseling

See Literature